|
ENOPH1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.55351295663786E-15 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.64757096854373E-12 |
| Normal-vs-Stage2 |
1.237990E-04 |
| Normal-vs-Stage3 |
1.45519996053167E-09 |
| Normal-vs-Stage4 |
3.81350000022707E-07 |
| Stage1-vs-Stage2 |
6.555200E-01 |
| Stage1-vs-Stage3 |
5.825600E-01 |
| Stage1-vs-Stage4 |
8.199000E-01 |
| Stage2-vs-Stage3 |
9.578600E-01 |
| Stage2-vs-Stage4 |
8.509200E-01 |
| Stage3-vs-Stage4 |
8.536000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.5896173266583E-12 |
| Normal-vs-AfricanAmerican |
1.076070E-03 |
| Normal-vs-Asian |
1.15970000047483E-07 |
| Caucasian-vs-AfricanAmerican |
4.921600E-01 |
| Caucasian-vs-Asian |
2.976200E-01 |
| AfricanAmerican-vs-Asian |
9.449400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.40459996148479E-09 |
| Normal-vs-Female |
9.99200722162641E-16 |
| Male-vs-Female |
1.565830E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.39084316181015E-12 |
| Normal-vs-Age(41-60Yrs) |
3.464595277336E-11 |
| Normal-vs-Age(61-80Yrs) |
2.26440000083983E-09 |
| Normal-vs-Age(81-100Yrs) |
6.844200E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.926600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.950600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.628400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.094800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.506400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.289600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.395900E-02 |
| Classical-VS-Follicular |
6.505200E-01 |
| Classical-VS-Other |
9.959400E-01 |
| Classical-VS-Normal |
1.67721392330122E-12 |
| Tall-VS-Follicular |
3.209400E-01 |
| Tall-VS-Other |
4.203400E-01 |
| Tall-VS-Normal |
7.50399999915885E-08 |
| Follicular-VS-Other |
8.902600E-01 |
| Follicular-VS-Normal |
2.95859999832615E-08 |
| Other-VS-Normal |
5.293900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.68830521679797E-11 |
| Normal-vs-N1 |
2.03809999999027E-05 |
| N0-vs-N1 |
6.351800E-01 |
|
|
